McKesson Plunges 3% After Strong Earnings: The Paradox of Profitable Distribution

Summary
• McKesson (MCK) shares drop 3.03% to $850.64 despite beating Q1 FY2027 EPS estimates
• Company raises full-year adjusted EPS guidance to $44.20–$45.00, signaling robust growth
• Eastern Bank slashes its MCK stake by 98.2%, while Horizon Investments boosts holdings by 125.4%
• Intraday range spans from a high of $912.50 to a low of $840.11, revealing intense volatility

McKesson’s stock is caught in a fierce battle between fundamental strength and institutional profit-taking. Despite delivering a stellar earnings report with revenue up 7.7% year-over-year and raising its outlook, the market reacted with a sharp sell-off, erasing earlier gains from the day’s open of $912.22. This divergence highlights a complex sentiment where institutional rebalancing and short-term technical exhaustion are overriding positive fundamental news.
Earnings Beat Ignites Institutional Rebalancing
The primary driver of McKesson’s intraday decline is a significant institutional portfolio adjustment rather than a deterioration in business fundamentals. While the company reported strong Q1 FY2027 results with $9.93 EPS, exceeding the $9.56 consensus, the market’s reaction was muted. The key catalyst for the drop is the disclosure that Eastern Bank reduced its position by 98.2%, selling 17,975 shares. Conversely, other institutions like Horizon Investments and Mirae Asset Global Investments increased their stakes. This mixed institutional activity, combined with the stock’s proximity to its 52-week high of $999, likely triggered profit-taking and algorithmic selling, causing the price to slide from its opening levels down to $850.64.

Healthcare Distributors Face Broad Pressure
The healthcare sector is showing signs of broad-based weakness, with sector leader AMN Healthcare Services (AMN) leading the decline with a steep intraday drop of 4.94%. This suggests that McKesson’s fall is not an isolated incident but part of a wider correction in the healthcare distribution and services space. While Roche reported positive 6% sales growth, the broader sector sentiment appears cautious, with leveraged healthcare ETFs like CURE (Direxion Daily Healthcare Bull 3X ETF) down 1.16% and RXL (ProShares Ultra Health Care) down 0.89%, indicating that systemic selling pressure is affecting even high-quality names like McKesson.

Technical Breakdown Signals Caution Amidst Support
The technical picture for McKesson is deteriorating, with the stock trading below its 200-day moving average of $836.80 and testing key support levels.
• 200-day moving average: 836.80 (above) - Price is currently hovering just above this critical long-term support line.
• RSI: 58.34 (neutral) - Indicates no immediate overbought or oversold condition, allowing for further downside.
• MACD Histogram: -0.22 (negative) - Suggests bearish momentum is building as the histogram turns negative.
• 30-day support: 761.73–764.57 (below) - A major safety net if the current support breaks.

The stock opened high at $912.50 but failed to hold, closing near the lower end of its range. The negative MACD histogram confirms that sellers are gaining control. While the options chain data is empty, preventing specific option picks, the technical setup suggests a bearish bias. The stock is trading between the 200-day MA ($836.80) and the 30-day MA ($815.98). If the $840 level fails to hold, a retest of the $815–$816 zone is likely. Traders should watch the $836.80 200-day moving average closely; a decisive break below could trigger a deeper correction toward the 30-day support at $761.73.

Hold Steady and Watch $836 Support
McKesson’s fundamental story remains intact with raised guidance and strong revenue growth, but the technical breakdown and institutional selling pressure suggest near-term headwinds. The stock’s ability to hold the $836.80 200-day moving average is critical for maintaining its long-term bullish structure. Investors should exercise caution and wait for a stabilization signal before adding positions. Watch for a breakdown below $836 or a rebound above $880 to confirm the next directional move. Meanwhile, sector leader AMN Healthcare Services (AMN) is down 4.94%, signaling that the entire healthcare distribution sector remains under pressure, reinforcing the need for selective entry points.